ArticlePediatric cardiology2026
Outcomes of Modified Microvascular Plugs as a Pulmonary Flow Restrictors in Congenital Heart Disease.
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Manually modified microvascular plugs (M-MVPs) have emerged as transcatheter pulmonary flow restrictors (PFRs) in neonates and infants with complex congenital heart disease and pulmonary overcirculation. Standardized device modification methods and short-term outcomes remain limited. We performed a retrospective single-center clinical data review of consecutive patients who underwent transcatheter pulmonary flow restriction using M-MVPs from January 2023 through June 2025. Data collected included patient characteristics, procedural details, peri-procedural complications, surgical outcomes, device explantation, and mortality. Twenty-one neonates and infants (median age: 16 days (IQR 8-22); median weight: 2.8 kg (IQR 2.3-3.9) received 44 M-MVP devices. Femoral venous access was used in 20/21 cases, with carotid access required in one patient. Median angiographic branch pulmonary artery diameters were 5.1 mm (left) and 5.3 mm (right). Fifteen patients underwent surgical explantation at a median 43 days (IQR 37.5-58.5 days), with one patient supported for 236 days. All devices were surgically explanted without major intraoperative complications or device related stenosis requiring pulmonary arterioplasty. Three patients required additional device implantation for distal migration or incomplete pulmonary artery coverage, and two patients ultimately required conversion to surgical main pulmonary artery banding. Interval mortality was 29% (6/21) in a cohort with substantial comorbidity, physiologic instability, and limited surgical candidacy. Exploratory physiologic analysis demonstrated higher renal near-infrared spectroscopy values among patients who survived to surgery, although physiologic responses following implantation were variable. In this retrospective descriptive experience, M-MVPs provided technically feasible temporary pulmonary flow restriction in carefully selected high-risk neonates and infants. Given the small sample size, heterogeneous cohort, and lack of a control group, the findings presented should be considered descriptive and hypothesis generating.
Indexed as
Identifiers
42579143What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.